Microcap Ledger enVVeno Medical Corp $NVNO
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Surgical & Medical Instruments & Apparatus
- Headquarters
- Irvine, CA
- Fiscal year end
- December 31
- Shares outstanding
- 682,722 [10-Q 2026-07-30]
What the company doesAI summary of filing
enVVeno Medical Corporation is a medical device company developing bioprosthetic venous valve solutions for the treatment of chronic venous insufficiency (CVI). The company's lead product candidate, the enVVe System, is a first-in-class, non-surgical, transcatheter-based replacement venous valve designed to treat severe CVI of the deep venous system; the company has completed pre-clinical testing and begun FDA discussions regarding a pivotal trial expected to begin in 2026. The company previously developed the VenoValve, a first-in-class surgical replacement venous valve, which received a not-approvable letter from the FDA in August 2025. enVVeno is currently pre-revenue and operates a 14,507 square foot ISO 13485-certified manufacturing facility in Irvine, California. [10-K 2026-03-26]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$7.45M | −$6.79M | $2.84M | [10-Q 2026-07-30] |
| FY ended Dec 2025 | — | −$19.47M | −$15.57M | $3.06M | [10-K 2026-03-26] |
| FY ended Dec 2024 | — | −$21.82M | −$16.84M | $1.75M | [10-K 2026-03-26] |
- Quarterly cash burn
- −$3.39M
- Cash runway Estimate
- ~2.5 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-10-28 | 17,536,000 | [10-Q 2024-10-31] |
| 2025-02-25 | 17,536,000 | [10-K/A 2025-02-28] |
| 2025-04-28 | 17,536,000 | [10-Q 2025-04-30] |
| 2025-07-29 | 19,247,141 | [10-Q 2025-07-31] |
| 2025-10-28 | 20,216,176 | [10-Q 2025-10-30] |
| 2026-03-24 | 655,521 | [10-K 2026-03-26] |
| 2026-05-01 | 667,669 | [10-Q 2026-05-06] |
| 2026-07-28 | 682,722 | [10-Q 2026-07-30] |
- Shelf registration
- S-3 filed 2026-08-21; no effectiveness notice found in EDGAR [S-3 2026-08-21]
Listing status
Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-10-10. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2025-10-10 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-10-10] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-11 | Duhay Francis | sell | 11 | $11.21 | [4 2026-09-14] |
| 2026-06-11 | Duhay Francis | sell | 140 | $10.30 | [4 2026-06-12] |
| 2026-03-12 | Duhay Francis | sell | 140 | $11.52 | [4 2026-03-13] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-15 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-08-21 | S-3 | Registration statement |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-07-30 | 10-Q | Quarterly report |
| 2026-07-14 | 8-K | Regulation FD disclosure |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-06 | 10-Q | Quarterly report |
| 2026-04-29 | 8-K | Results of operations; Regulation FD disclosure; Other events |
| 2026-03-26 | 10-K | Annual report |
| 2026-02-20 | 13D | Beneficial ownership report (5%+ holder) |
| 2026-02-20 | 13D | Beneficial ownership report (5%+ holder) |
Alerts for $NVNO
Email me when enVVeno Medical Corp files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.